{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0037751\nAge: 74\nGender: Male\nSample ID: P-0037751-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Prostate Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nFOXA1 c.798C>A (p.F266L) - in 26.00% of 709 reads\nCNA Data:\nSOX17 - High Level Amplification\nPRDM1 - Homozygous Deletion\nMAP3K1 - Homozygous Deletion\nSESN1 - Homozygous Deletion\nFOXO1 - Homozygous Deletion\nPLCG2 - Homozygous Deletion\nMAP3K14 - Homozygous Deletion\nROS1 - Homozygous Deletion\nCYLD - Homozygous Deletion\nPAK7 - Homozygous Deletion\nRECQL4 - High Level Amplification\nZFHX3 - Homozygous Deletion\nFYN - Homozygous Deletion\nGPS2 - Homozygous Deletion\nBRCA2 - Homozygous Deletion\nFGFR1 - Homozygous Deletion\nPNRC1 - Homozygous Deletion\nTP53 - Homozygous Deletion\nLYN - High Level Amplification\nPLK2 - Homozygous Deletion\nWHSC1L1 - Homozygous Deletion\nMYC - High Level Amplification\nMST1R - High Level Amplification\nPREX2 - High Level Amplification\nRAD21 - High Level Amplification\nAGO2 - High Level Amplification\nEPHA7 - Homozygous Deletion\nDUSP4 - Homozygous Deletion\nNKX3-1 - Homozygous Deletion\nStructural Variants:\nST7 - MET (DUPLICATION)\nTMPRSS2 - ERG (DELETION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Androgen Receptor Signaling Inhibitors (e.g., Enzalutamide, Abiraterone)\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": [\n      \"TMPRSS2-ERG deletion\",\n      \"High level amplification of MYC, MST1R, PREX2, RAD21, AGO2\",\n      \"Homozygous deletions in BRCA2, TP53, NKX3-1, and other tumor suppressors\",\n      \"MET duplication (ST7)\",\n      \"FOXA1 mutation (c.798C>A, p.F266L)\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/enzalutamide and https://www.fda.gov/drugs/resources-information-approved-drugs/abiraterone-acetate\"\n  }\n}"
}